All In Biotech

BLA 761279 · Eli Lilly and CO

Omvoh

Mirikizumab-Mrkz · Subcutaneous, Single-Use · Interleukin-23 Antagonist

NovelOrphan

CDER novel approval, Oct 26, 2023: To treat ulcerative colitis

Last checked: Nov 20, 2026Latest source record: Oct 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Oct 26, 2023

Approved uses

3

Original approval plus efficacy supplements

Registered trials

51

15 Phase 3, 12 recruiting

FAERS reports

903

489 serious, 26 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 16, 2026.

OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults. OMVOH TM is an interleukin-23 antagonist indicated for the treatment of: moderately to severely active ulcerative colitis in adults ( 1 ) moderately to severely active Crohn's disease in adults ( 1 )

Mechanism: Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is involved in mucosal inflammation and affects the differentiation, expansion, and survival of T cell subsets, and innate immune cell subsets, which represent sources of pro-inflammatory cytokines. Research in animal models has shown that pharmacologic inhibition of IL-23p19 can ameliorate intestinal inflammation. Mirikizumab-mrkz inhibits the release of pro-inflammatory cytokines and chemokines.

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • OMVOH · MIRIKIZUMAB-MRKZ 100MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription
  • OMVOH · MIRIKIZUMAB-MRKZ 300MG/15ML · VIAL, SINGLE-USE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mirikizumab" as an intervention, any sponsor and status, largest first.

All 51 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • colitis ulcerative155
  • injection site pain89
  • drug ineffective81
  • diarrhoea37
  • haematochezia35
  • arthralgia30
  • incorrect dose administered29
  • headache27
  • rash27
  • frequent bowel movements25
  • off label use24
  • maternal exposure during pregnancy23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202322
2024312
2025318
2026251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Dec 22, 2025

    Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27). A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.

  • To Be Discontinued · updated Dec 22, 2025

    Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27). A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Omvoh* (Mirikizumab-Mrkz)

2024 spending

$1.1M

Beneficiaries

42

107 claims

Per beneficiary

$26,594

$1,104.07 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,116,928

Part B: Omvoh* (Mirikizumab-Mrkz*) · HCPCS J2267

2024 spending

$1.1M

Beneficiaries

54

110 claims

Per beneficiary

$21,213

2024 ASP limit $37.14 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,145,487

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 70 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.